About

The Afimmune management team has both a strong background in developing drugs for the market and experience in building life science companies.

Pipeline

Afimmune has assets in various stages of clinical and pre-clinical development.

Investors

To date, Afimmune has been funded privately.

Latest News

November 5, 2025
Published by Melanie Hurley Iveagh at November 5, 2025
Categories

Afimmune to host session before and present at the 67th American Society of Hematology (ASH) Annual Meeting after completing Sickle Cell Disease trial enrolment.

Dublin, Ireland, 5 November 2025: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that enrolment has successfully completed in the first clinical trial […]
Do you like it?0
Read more
September 19, 2024
Published by Melanie Hurley Iveagh at September 19, 2024
Categories

Epeleuton for Sickle Cell Disease receives key US patent grant

Dublin, Ireland, 18th September 2024 – Afimmune, a clinical stage drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued […]
Do you like it?0
Read more

More Press Releases

Join our mailing list

Connect with us

Contact us

t: +353 1 2933 590
e: [email protected]